{"id":94153,"date":"2026-05-22T15:42:10","date_gmt":"2026-05-22T15:42:10","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/94153\/"},"modified":"2026-05-22T15:42:10","modified_gmt":"2026-05-22T15:42:10","slug":"jeste-ucinejsi-nez-ozempic-zazracny-lek-nove-generace-je-prulomovy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/94153\/","title":{"rendered":"Je\u0161t\u011b \u00fa\u010din\u011bj\u0161\u00ed ne\u017e Ozempic. Z\u00e1zra\u010dn\u00fd l\u00e9k nov\u00e9 generace je pr\u016flomov\u00fd"},"content":{"rendered":"

Farmaceutick\u00e1 spole\u010dnost Eli Lilly ozn\u00e1mila dal\u0161\u00ed pr\u016flom<\/a> v l\u00e9\u010db\u011b obezity. Jej\u00ed experiment\u00e1ln\u00ed p\u0159\u00edpravek retatrutid \u00fasp\u011b\u0161n\u011b pro\u0161el rozs\u00e1hlou klinickou studi\u00ed t\u0159et\u00ed f\u00e1ze a podle zve\u0159ejn\u011bn\u00fdch v\u00fdsledk\u016f pomohl pacient\u016fm zhubnout v\u00edce ne\u017e jak\u00fdkoli dosud schv\u00e1len\u00fd l\u00e9k na obezitu. N\u011bkte\u0159\u00ed \u00fa\u010dastn\u00edci studie b\u011bhem l\u00e9\u010dby ztratili a\u017e t\u0159etinu sv\u00e9 p\u016fvodn\u00ed t\u011blesn\u00e9 hmotnosti, co\u017e je v\u00fdsledek dosud spojovan\u00fd p\u0159edev\u0161\u00edm s bariatrick\u00fdmi operacemi.<\/p>\n

V\u00fdsledky p\u0159edstavuj\u00ed d\u016fle\u017eit\u00fd miln\u00edk pro spole\u010dnost Eli Lilly, kter\u00e1 se d\u00edky \u00fasp\u011b\u0161n\u00fdm p\u0159\u00edpravk\u016fm Zepbound a Mounjaro stala jedn\u00edm z hlavn\u00edch hr\u00e1\u010d\u016f na rychle rostouc\u00edm trhu s l\u00e9ky na hubnut\u00ed. Firma se nyn\u00ed p\u0159ibl\u00ed\u017eila k pod\u00e1n\u00ed \u017e\u00e1dosti o schv\u00e1len\u00ed retatrutidu regula\u010dn\u00edmi \u00fa\u0159ady. Pokud l\u00e9k z\u00edsk\u00e1 povolen\u00ed k uveden\u00ed na trh, mohl by v\u00fdrazn\u011b prom\u011bnit sou\u010dasnou l\u00e9\u010dbu obezity.<\/p>\n

\u0160ir\u0161\u00ed vzorek<\/p>\n

Do studie<\/a> bylo za\u0159azeno p\u0159ibli\u017en\u011b 2 500 dosp\u011bl\u00fdch pacient\u016f s obezitou. Lid\u00e9 u\u017e\u00edvaj\u00edc\u00ed nejvy\u0161\u0161\u00ed d\u00e1vku retatrutidu zhubli b\u011bhem 80 t\u00fddn\u016f v pr\u016fm\u011bru 28,3 procenta sv\u00e9 t\u011blesn\u00e9 hmotnosti. V p\u0159epo\u010dtu to p\u0159edstavuje v\u00edce ne\u017e 31 kilogram\u016f. Pro srovn\u00e1n\u00ed, pacienti u\u017e\u00edvaj\u00edc\u00ed placebo ztratili pouze 2,2 procenta sv\u00e9 hmotnosti. T\u00e9m\u011b\u0159 polovina \u00fa\u010dastn\u00edk\u016f l\u00e9\u010dby p\u0159itom dos\u00e1hla \u00fabytku v\u00e1hy alespo\u0148 o 30 procent.<\/p>\n

Je\u0161t\u011b v\u00fdrazn\u011bj\u0161\u00ed v\u00fdsledky p\u0159ineslo dlouhodob\u011bj\u0161\u00ed sledov\u00e1n\u00ed pacient\u016f s t\u011b\u017e\u0161\u00ed formou obezity. U lid\u00ed s indexem t\u011blesn\u00e9 hmotnosti (BMI) vy\u0161\u0161\u00edm ne\u017e 35 dos\u00e1hl pr\u016fm\u011brn\u00fd pokles v\u00e1hy po dvou letech l\u00e9\u010dby 30,3 procenta. P\u0159ibli\u017en\u011b dv\u011b t\u0159etiny pacient\u016f u\u017e\u00edvaj\u00edc\u00edch nejvy\u0161\u0161\u00ed d\u00e1vku se nav\u00edc dostaly pod hranici BMI 30, kter\u00e1 odd\u011bluje obezitu od nadv\u00e1hy.<\/p>\n

V \u010dem se li\u0161\u00ed od Ozempicu a Wegovy?<\/p>\n

Obrovsk\u00fd z\u00e1jem o retatrutid vyvol\u00e1v\u00e1 p\u0159edev\u0161\u00edm jeho odli\u0161n\u00fd mechanismus \u00fa\u010dinku. Sou\u010dasn\u00e9 popul\u00e1rn\u00ed l\u00e9ky na hubnut\u00ed, mezi kter\u00e9 pat\u0159\u00ed Ozempic a Wegovy od spole\u010dnosti Novo Nordisk nebo Zepbound od Eli Lilly, funguj\u00ed na principu napodobov\u00e1n\u00ed hormon\u016f, kter\u00e9 reguluj\u00ed chu\u0165 k j\u00eddlu a hladinu cukru v krvi.<\/p>\n

Semaglutid, \u00fa\u010dinn\u00e1 l\u00e1tka v p\u0159\u00edpravc\u00edch Ozempic a Wegovy, napodobuje hormon GLP-1. Tirzepatid, kter\u00fd obsahuje Mounjaro \u010di\u00a0Zepbound, p\u016fsob\u00ed sou\u010dasn\u011b na hormony GLP-1 a GIP. Retatrutid jde je\u0161t\u011b o krok d\u00e1l. Ovliv\u0148uje toti\u017e hned t\u0159i hormon\u00e1ln\u00ed dr\u00e1hy \u2013 GLP-1, GIP a glukagon. Pr\u00e1v\u011b proto b\u00fdv\u00e1 ozna\u010dov\u00e1n jako \u201etriple G\u201c.<\/p>\n

Kombinace t\u011bchto t\u0159\u00ed mechanism\u016f m\u00e1 podle v\u00fdzkumn\u00edk\u016f dvoj\u00ed efekt. Na jedn\u00e9 stran\u011b v\u00fdrazn\u011b sni\u017euje chu\u0165 k j\u00eddlu a prodlu\u017euje pocit sytosti, na stran\u011b druh\u00e9 podporuje energetick\u00fd v\u00fddej organismu. V\u00fdsledkem je rychlej\u0161\u00ed a v\u00fdrazn\u011bj\u0161\u00ed pokles t\u011blesn\u00e9 hmotnosti ne\u017e u sou\u010dasn\u00fdch p\u0159\u00edpravk\u016f.<\/p>\n

U\u017e p\u0159ed zve\u0159ejn\u011bn\u00edm studie se o\u010dek\u00e1valo, \u017ee retatrutid p\u0159ekon\u00e1 \u00fa\u010dinnost l\u00e9ku Zepbound, kter\u00fd ve studi\u00edch vykazoval pr\u016fm\u011brn\u00fd \u00fabytek hmotnosti kolem 20 a\u017e 22 procent. Nov\u00e9 v\u00fdsledky tato o\u010dek\u00e1v\u00e1n\u00ed potvrdily.<\/p>\n

Zaj\u00edmav\u00e9 je, \u017ee firma testovala tak\u00e9 dosud nezkou\u0161enou ni\u017e\u0161\u00ed d\u00e1vku \u010dty\u0159i miligramy. Ta vedla k pr\u016fm\u011brn\u00e9mu poklesu hmotnosti \u201ejen\u201c o 19 procent, tedy p\u0159ibli\u017en\u011b na \u00farovni v\u00fdsledk\u016f dosa\u017een\u00fdch vysok\u00fdmi d\u00e1vkami sou\u010dasn\u00fdch l\u00e9k\u016f. Sou\u010dasn\u011b v\u0161ak vyk\u00e1zala v\u00fdrazn\u011b lep\u0161\u00ed sn\u00e1\u0161enlivost a m\u00e9n\u011b vedlej\u0161\u00edch \u00fa\u010dink\u016f.<\/p>\n

Vedlej\u0161\u00ed \u00fa\u010dinky p\u0159ipom\u00ednaj\u00ed sou\u010dasn\u00e9 l\u00e9ky<\/p>\n

P\u0159esto\u017ee v\u00fdsledky studie p\u016fsob\u00ed velmi slibn\u011b, retatrutid nen\u00ed bez rizik. Podobn\u011b jako ostatn\u00ed l\u00e9ky zalo\u017een\u00e9 na p\u016fsoben\u00ed hormon\u016f GLP-1 vyvol\u00e1val p\u0159edev\u0161\u00edm za\u017e\u00edvac\u00ed obt\u00ed\u017ee.<\/p>\n

Nej\u010dast\u011bj\u0161\u00edm probl\u00e9mem byla nevolnost, kter\u00e1 postihla zhruba 42 procent pacient\u016f u\u017e\u00edvaj\u00edc\u00edch nejvy\u0161\u0161\u00ed d\u00e1vku. P\u0159ibli\u017en\u011b t\u0159etina \u00fa\u010dastn\u00edk\u016f m\u011bla pr\u016fjem a v\u00edce ne\u017e \u010dtvrtina trp\u011bla z\u00e1cpou. Tyto obt\u00ed\u017ee se objevuj\u00ed i u jin\u00fdch modern\u00edch l\u00e9k\u016f na hubnut\u00ed a odborn\u00edci je pova\u017euj\u00ed za o\u010dek\u00e1van\u00fd d\u016fsledek jejich mechanismu \u00fa\u010dinku.<\/p>\n

L\u00e9ka\u0159i zaznamenali tak\u00e9 vy\u0161\u0161\u00ed v\u00fdskyt infekc\u00ed horn\u00edch cest d\u00fdchac\u00edch a mo\u010dov\u00fdch cest. U v\u00edce ne\u017e 12 procent pacient\u016f se objevila takzvan\u00e1 dysestezie, tedy nep\u0159\u00edjemn\u00e9 pocity p\u00e1len\u00ed, mraven\u010den\u00ed nebo jin\u00fdch nervov\u00fdch vjem\u016f. Tento vedlej\u0161\u00ed \u00fa\u010dinek byl pozorov\u00e1n u\u017e v p\u0159edchoz\u00edch studi\u00edch retatrutidu.<\/p>\n

Vedlej\u0161\u00ed \u00fa\u010dinky byly nej\u010dast\u011bj\u0161\u00edm d\u016fvodem ukon\u010den\u00ed l\u00e9\u010dby. U nejvy\u0161\u0161\u00ed d\u00e1vky p\u0159eru\u0161ilo terapii p\u0159ibli\u017en\u011b 11 procent pacient\u016f, zat\u00edmco u nejni\u017e\u0161\u00ed d\u00e1vky to byla pouze \u010dty\u0159i procenta. To je dokonce m\u00e9n\u011b ne\u017e ve skupin\u011b u\u017e\u00edvaj\u00edc\u00ed placebo.<\/p>\n

Boj o miliardov\u00fd trh<\/p>\n

\u00dasp\u011bch<\/a> retatrutidu p\u0159ich\u00e1z\u00ed v dob\u011b, kdy farmaceutick\u00e9 firmy sv\u00e1d\u011bj\u00ed tvrd\u00fd boj<\/a> o dominanci na trhu s l\u00e9ky proti obezit\u011b.\u00a0Eli Lilly je v sou\u010dasnosti v \u010dele tohoto trhu a podle \u00fadaj\u016f spole\u010dnosti dr\u017eela v prvn\u00edm \u010dtvrtlet\u00ed leto\u0161n\u00edho roku p\u0159ibli\u017en\u011b 60 procent americk\u00e9ho trhu s l\u00e9ky na obezitu a diabetes. Konkuren\u010dn\u00ed Novo Nordisk ovl\u00e1dala necel\u00fdch 40 procent.<\/p>\n

Pr\u00e1v\u011b retatrutid m\u00e1 b\u00fdt jedn\u00edm z kl\u00ed\u010dov\u00fdch produkt\u016f, kter\u00e9 spole\u010dnosti Lilly pomohou si n\u00e1skok udr\u017eet. Analytici investi\u010dn\u00ed spole\u010dnosti TD Cowen<\/a> odhaduj\u00ed, \u017ee samotn\u00fd tento l\u00e9k by mohl v roce 2030 generovat tr\u017eby kolem 3,8 miliardy dolar\u016f ro\u010dn\u011b.<\/p>\n

Konkurence v\u0161ak nezah\u00e1l\u00ed. Novo Nordisk u\u017e pracuje na vlastn\u00ed generaci takzvan\u00fdch trojit\u00fdch agonist\u016f a letos ozn\u00e1mila miliardovou investici do v\u00fdvoje podobn\u00e9ho experiment\u00e1ln\u00edho p\u0159\u00edpravku. Jeho uveden\u00ed na trh je ale podle odborn\u00edk\u016f je\u0161t\u011b n\u011bkolik let vzd\u00e1len\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"Farmaceutick\u00e1 spole\u010dnost Eli Lilly ozn\u00e1mila dal\u0161\u00ed pr\u016flom v l\u00e9\u010db\u011b obezity. Jej\u00ed experiment\u00e1ln\u00ed p\u0159\u00edpravek retatrutid \u00fasp\u011b\u0161n\u011b pro\u0161el rozs\u00e1hlou klinickou…\n","protected":false},"author":2,"featured_media":94154,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[12],"tags":[67,68,28593,28592,5545,2813,14812,5294,7604,4908,28594,28595],"class_list":["post-94153","post","type-post","status-publish","format-standard","has-post-thumbnail","category-byznys","tag-business","tag-byznys","tag-eli-lilly","tag-hormon","tag-hubnuti","tag-lecba","tag-novo-nordisk","tag-obezita","tag-ozempic","tag-pacient","tag-tirzepatide","tag-vedlejsi-ucinek"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116618995039709440","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/94153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=94153"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/94153\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/94154"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=94153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=94153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=94153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}